Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Umbilical Cord Mesenchymal Stem Cells(Shanghai East Hospital) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
Umbilical Cord Mesenchymal Stem Cells(Shanghai East Hospital): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical.
8 min read
Human retinal pigment epithelial cell therapy (Astellas Pharma) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
Human retinal pigment epithelial cell therapy (Astellas Pharma): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical.
8 min read
Donor-derived Natural Killer Cell(Federal Research Institute of Pediatric Hematology) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
Donor-derived Natural Killer Cell(Federal Research Institute of Pediatric Hematology): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review.
8 min read
Allogeneic platelet lysate(Pavlov First Saint Petersburg State Medical University) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
Allogeneic platelet lysate(Pavlov First Saint Petersburg State Medical University): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review.
8 min read
GC-3111 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
GC-3111: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
18F-92 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
18F-92: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
FF-10502 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
FF-10502: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
SK-NBP615 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
SK-NBP615: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
VT-1092 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
VT-1092: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
S-525606 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
S-525606: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
MTX-101 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
MTX-101: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
NBI-1065890 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
NBI-1065890: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.